Transcriptional Regulation of Dendritic Cell Diversity by Michaël Chopin et al.
REVIEW ARTICLE
published: 27 February 2012
doi: 10.3389/ﬁmmu.2012.00026
Transcriptional regulation of dendritic cell diversity
Michaël Chopin, Rhys S. Allan and GabrielleT. Belz*
Division of Molecular Immunology, The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
Edited by:
Christian Kurts, Friedrich
Wilhelms-Universität Bonn, Germany
Reviewed by:
Oliver Pabst, Hannover Medical
School, Germany
Natalio Garbi, German Cancer
Research Center DKFZ, Germany
*Correspondence:
Gabrielle T. Belz, Division of Molecular
Immunology, Walter and Eliza Hall
Institute of Medical Research, 1G
Royal Parade, Parkville, Melbourne,
VIC 3052, Australia.
e-mail: belz@wehi.edu.au
Dendritic cells (DCs) are specialized antigen presenting cells that are exquisitely adapted
to sense pathogens and induce the development of adaptive immune responses. They
form a complex network of phenotypically and functionally distinct subsets. Within this
network, individual DC subsets display highly speciﬁc roles in local immunosurveillance,
migration, and antigen presentation.This division of labor amongst DCs offers great poten-
tial to tune the immune response by harnessing subset-speciﬁc attributes of DCs in the
clinical setting. Until recently, our understanding of DC subsets has been limited and paral-
leled by poor clinical translation and efﬁcacy.We have now begun to unravel how different
DC subsets develop within a complex multilayered system. These ﬁndings open up excit-
ing possibilities for targeted manipulation of DC subsets. Furthermore, ground-breaking
developments overcoming a major translational obstacle – identiﬁcation of similar DC pop-
ulations in mouse and man – now sets the stage for signiﬁcant advances in the ﬁeld. Here
we explore the determinants that underpin cellular and transcriptional heterogeneity within
the DC network, how these inﬂuence DC distribution and localization at steady-state, and
the capacity of DCs to present antigens via direct or cross-presentation during pathogen
infection.
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INTRODUCTION
Dendritic cells (DCs) are a heterogeneous population of rare
hematopoietic cells that are present in most tissues and are essen-
tial to the induction of both immunity and tolerance (Steinman
and Witmer, 1978; Birnberg et al., 2008; Ohnmacht et al., 2009).
They are organized as a specialized“network” that enables them to
sample antigens from their environment which are then presented
to other lymphocytes. As such, this elegant arm of the immune
system is dedicated to shaping the immune response to peripheral
antigens.
Dendritic cells are distinct from other immune cells as they
are equipped with molecular machinery that enables them to
very efﬁciently take up, process, and present antigens on major
histocompatibility (MHC) class I and II molecules to T cells.
In addition, they are equiped with a range of pathogen sens-
ing molecules such as toll-like receptors (TLRs), nucleotide-
binding oligomerization domain proteins, retinoid-inducible gene
1-like receptors, and C-type lectins that allow them to detect
pathogen products and sense inﬂammation. Signaling through
these receptors triggers migration of DCs from peripheral tis-
sues to secondary lymphoid organs bringing DCs carrying anti-
gens into close association with T cells. This pathway pro-
vides the critical link between the external environment (the
major entry point for pathogens) and the sites where organized
immune responses are induced, the lymph nodes (Randolph et al.,
2008).
Abbreviations: APCs, antigen presenting cells; DCs, dendritic cells; HSV, herpes
simplex virus; IL, interleukin; LP, lamina propria; MHC, major histocompatibility
complex; n.d., not determined.
In recent years a number of distinct DC subsets have been
deﬁned. These subsets have been based largely on long standing
criteria that relies on the expression of speciﬁc cell-surface mark-
ers. More recently, understanding the development and contri-
butions of these DC subsets to immunity has been broadened
signiﬁcantly by insights to the ontogeny of the different subsets
and the transcription factors that guide their development. Here
we will highlight recent studies deciphering the transcriptional
regulation that underpins DC heterogeneity which is critical in
defense against pathogen infection.
ARCHITECTURE OF THE DC NETWORK
On the October 3, 2011, DCs took center stage in the scientiﬁc
world with the awarding of the Nobel Prize for Physiology or
Medicine to Ralph Steinman together with Bruce Beutler and Jules
Hoffmann for revolutionizing our understanding of the immune
system by discovering key principles for its activation. Hoffman
pioneered the discovery of sensingmolecules in fruit ﬂies enabling
them to combat infection (Lemaitre et al., 1996), while Beutler
uncovered the homologous receptors in mice that could detect
pathogen products (Poltorak et al., 1998). More than a decade
earlier, Ralph Steinman had discovered a rare cell type, the DC,
within the immune system that had a unique capacity to efﬁciently
activate immune cells (Steinman and Cohn, 1973). Since then, it
has been shown that DCs express a wide range of innate recep-
tors that enable pathogen sensing and the initiation of protective
immunity.
Cardinal features of DCs are (i) their ability to efﬁciently take
up and present self and pathogen-derived antigens to other cells of
the immune system such as T cells and B cells, and (ii) their capac-
ity to migrate from peripheral tissues such as skin and mucosa to
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FIGURE 1 | Architecture of the DC network.The DC network is composed
of multiple DC subsets that are broadly divided into cDCs, pDCs, MoDCs, and
LCs which have distinct anatomical localizations in tissues. (A) Migratory DCs
in peripheral tissues sample antigen from the periphery and then migrate
through the lymphatic vessels to the afferent lymph node to present
captured-processed antigens to theT cell within theT cell zone. In peripheral
tissues, such as the skin, three main DC subsets are found. Dermal DCs are
composed of the CD103+CD11b− DC and CD11b+ DC. Both arise from a
pre-DC that homed to the tissue. Under conditions of inﬂammation, some
CD11b+ DC can be derived from a monocytic precursor. In addition to the
dermal DCs, the epidermis of the skin is populated by the LCs which are
derived from a Ly6C+ progenitor. (B) In secondary lymphoid tissues such as
spleen, CD4+, CD8α+, and CD4−CD8α− or double negative (DN) DCs are
found. These subsets are also found in the draining lymph nodes which also
receive the inﬂux of the migratory CD11b+, CD103+CD11b− DCs, and LCs
arriving from the peripheral tissues.
secondary lymphoid tissues where they can activate lymphocytes
and initiate the immune response. This migratory behavior is
pivotal and provides a critical cellular link between the exter-
nal environment where pathogens might enter the body and the
secondary lymphoid tissueswhere immune responses are initiated.
A signature of DCs is their heterogeneity. The DC network is
composed of multiple subtypes of DCs that vary in their ori-
gin, anatomical localization, lifespan, and function (Figure 1).
Unraveling the developmental history of these subtypes has been
complicated in part by the rarity of DCs in tissues (∼1% of cells)
and their short lifespan. This was compounded by the early dif-
ﬁculties in establishing the growth factors and culture conditions
necessary for generating large numbers in vitro. However, recent
studies have made signiﬁcant progress in clarifying a number of
these steps.
Simplistically, four major populations of DCs have been
described (Figure 1), namely the conventional DCs (cDCs),
plasmacytoid DCs (pDCs), Langerhans cells (LCs), and the
monocyte-derived DCs (MoDCs).
CONVENTIONAL DCs
Conventional DCs can be divided into two main groups of cells.
They are (i) themigratory DCs and (ii) the lymphoid tissue-resident
DCs (Figure 1).
Migratory DCs reside in peripheral tissues such as the skin
and mucosa where they efﬁciently sample environmental antigens
and then migrate from to the regional lymph node in afferent
lymphatics to present antigens to T cells. They are composed
of the dermal or interstitial DCs and can be divided into the
CD11b+ and CD11b− DCs (Figure 1A). These DCs may also
express the integrin αE, also known as CD103. CD103 is expressed
on CD11b− DCs and can be found in a variety of others tissues.
However, in intestinal tissues, CD103 is expressed on CD11b+
DCs. Despite a similarity in expression of surface molecules by
these two DC subsets, the transcriptional machinery regulating
these two populations is distinctly different as discussed below.
The second category of cDCs is composed of several subsets
of DCs that are known as tissue-resident DCs. In contrast to their
migratory counterparts, they do not circulate through peripheral
tissues and thus can only process antigens found within the tis-
sue in which they are localized (Figure 1B). To overcome this
potentially limited access to antigen, migratory DCs can transfer
antigens to lymphoid resident DCs who via the process of cross-
presentation, provide an alternate strategy for the ampliﬁcation of
CD8+ T cell responses (Belz et al., 2004a; Allan et al., 2006).
Tissue-resident DCs are delineated by the expression of the
surface molecules CD4 and CD8α and are found in secondary
lymphoid organs such as the thymus, spleen, and lymph nodes.
Three subsets have been deﬁned which are (i) the CD4+ DCs,
(ii) the CD8α+ DCs, and (iii) the CD4−CD8α− (double negative,
DN) DCs. These subsets develop in situ from a common precur-
sor generated in the bone marrow that homes to the lymphoid
organs where they undergo further differentiation into mature
DC subsets (Naik et al., 2006). Although there are a number of
shared functions between these subsets, an interesting division
of labor has emerged: CD8α+ DCs are highly efﬁcient in direct
and cross-presentation of soluble, cell-associated (Table 1), and
pathogen-derived antigens to CD8+ T cells. Although CD4+ DCs
and CD4−CD8α− DCs can also present MHC class I-restricted
antigens in some settings (Kim and Braciale, 2009; Lukens et al.,
Frontiers in Immunology | Antigen Presenting Cell Biology February 2012 | Volume 3 | Article 26 | 2
Chopin et al. Transcriptional regulation of DC subsets
Table 1 | Features of cross-presenting antigen presenting cells.
DC Subset
Molecule CD8α+ DCs CD103+ DC
peripheral
tissues
Monocyte-
derived
DCs
Reference
XCR1 + + n.d. Dorner et al. (2009)
Clec9a + + − Caminschi et al. (2008), Sancho et al. (2009),
Hashimoto et al. (2011)
Mannose receptor + n.d. n.d. Burgdorf et al. (2006)
CD36 + + + Albert et al. (1998), Belz et al. (2002b), Desch et al. (2011)
E-cadherin n.d. n.d. + Siddiqui et al. (2010)
TLR3 + + n.d. Schulz et al. (2005), Jelinek et al. (2011)
Cytochrome c/Apaf-1 mediated death + n.d. n.d. Lin et al. (2008)
Migratory No Yes n.t. del Rio et al. (2010)
Involved in pathogen infection Yes Yes Yes Belz et al. (2004b), Allan et al. (2006), Bedoui et al. (2009)
Cross-presentation Constitutive
soluble and
cell-associated
Constitutive
soluble and
cell-associated
Induced in
inﬂammation
(TLR4)
den Haan et al. (2000), Jackson et al. (2011)
n.d., Not determined.
2009). They are more potent in presenting MHC II antigens to
CD4+ T cells (Allenspach et al., 2008; Mount et al., 2008).
CD8α+ and CD103+ DCs – drivers of cross-presentation
The CD8α+ and CD103+ DCs are cDCs that are of special inter-
est due to their shared functional attributes in driving immune
responses to pathogen infections, their capacity to cross-present
antigens, and the potential to harness the human equivalents of
these subsets for clinical use (Steinman, 2010).What distinguishes
these two subsets functionally and transcriptionally has thus been
an area of intense investigation.
The CD8α+ DC subset. CD8α+ DCs are distinct from other con-
ventional murine DC subsets by their unique surface expression
of a CD8αα homodimer. This non-migratory, lymphoid tissue-
residentDChas been shown to be key drivers of cross-presentation
to a range of experimental pathogen antigens both in vitro and
in vivo. CD8α+ DCs have been found to be critical for cross-
presentation of self-antigens resulting in the induction of immune
tolerance (Belz et al., 2002a; Heath et al., 2004). This subset was
also identiﬁed as themain subset involved in presenting pathogen-
derived antigens (Allan et al., 2003; Belz et al., 2004a,b, 2005;
Lemos et al., 2004; Neuenhahn et al., 2006; Edelson et al., 2011).
A number of mechanisms have been proposed to explain their
constitutive ability to cross-present antigens. These include the
expression of a number of surface receptors, such as CD36 and
Clec9a, that allow them to uptake dead or dying cells, specialized
intracellular pathways, and regulation of the pH in the phagosome
(Table 1). This antigen presenting function and their produc-
tion of interleukin-12 (IL-12) distinguish the CD8α+ DCs from
their CD8α− counterparts. Although initially cross-presentation
by CD8α+ DCs was thought to be a unique property restricted
solely to this subset, it is now clear that other DC subsets can
act as potent cross-presenting cells (i.e., CD103+ DC subset and
MoDCs, Table 1).
The CD103+ DC subset. This unusual DC subset that appeared
to be related to CD8α+ DCs was ﬁrst described in the inﬂuenza
infection and was characterized by the lack of expression of CD8α
and CD11b (CD8α−CD11b−; Belz et al., 2004b). It was found in
a number of lymph nodes including the inguinal, brachial, super-
ﬁcial cervical, mediastinal, mesenteric, hepatic, and renal nodes.
This DC subset presents viral antigens very efﬁciently suggesting
that CD8α−CD11b− DCs may play an important role in T cell
mediated immunity. It was postulated that these cells could trafﬁc
to the lymph nodes, thereby providing a critical link between anti-
gen sampling in peripheral tissues and antigen presentation in the
lymph node. Furthermore it was speculated that these cells would
be capable of cross-presentation. Following this early report, it
was discovered that these DCs expressed the molecules integrin
αE (CD103) and langerin (Sung et al., 2006). Following on from
the establishment of the importance of CD8α+ DC in promoting
viral immunity (Allan et al., 2003), CD103+ (langerin+) dermal
DCs, and lung CD103+ DCs have emerged as a potent migratory
DC able to process and load self- and viral antigens onto MHC
class I molecules (Sung et al., 2006; Bedoui et al., 2009).
PLASMACYTOID DCs
Plasmacytoid DCs express several key molecules that distinguish
them from the cDC subsets. These include the sialic acid-binding
immunoglobulin like lectin H (Siglec-H), Lilra4 (also known as
ILT7), bone marrow stromal antigen-2 (BST2, also known as teth-
erin) and blood DC antigen-2 (BDCA-2, also known as CLEC4C),
and the CD45RA isoform (Reizis et al., 2011). The hallmark prop-
erty of pDCs is their capacity to rapidly secrete type I interferons
(IFN-α) during viral infection. This is in part attributable to their
expression of TLR7 and TLR9 that enables sensing of nucleic
acids during viral infection. The antigen presentation potency of
pDCs is poor and although this can be enhanced during matu-
ration (Colonna et al., 2004), their low expression of MHC and
co-stimulatory molecules compared to their cDCs counterparts
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provide some explanation for their inefﬁciency in priming of
T cells.
LANGERHANS CELLS
Langerhans cells are a unique DC subset found within the epider-
mis of the skin andmucosa and contain large tennis racquet shaped
granules known as Birbeck granules of which langerin is a crucial
component. Initially, it was thought that langerin expression was
restricted solely to LCs, but it has more recently been discovered
that DC subsets located in the lamina propria of skin, bronchi,
and mucosa also express langerin (Bursch et al., 2007; Ginhoux
et al., 2007; Poulin et al., 2007). Despite sharing the expression of
langerin, other langerin+ DCs can arise along a different develop-
mental pathwaydistinct fromLCs (Merad et al., 2008). LCsdevelop
from a local LY6C+ myelo-monocytic precursor cell population,
and their development is dependent on TGF-β signaling (Chorro
et al., 2009; Nagao et al., 2009), while langerin+ DC develop from
a bone marrow precursor that is dependent on Fms-like tyrosine
kinase 3 (Flt3) signaling. LCs are exquisitely positioned to provide
the front line of defense of the immune system against external
invading pathogens. As LCs are the only cells that express MHC
II in the epidermis under non-inﬂammatory conditions and since
they are able to migrate through the dermis to the skin-draining
lymph nodes, LCs have been believed to be critical to promote
immunity, i.e., after skin infection.
This classical paradigm has been recently challenged. LCs are
largely resistant to γ-irradiation, a characteristic that has been
taken advantage of in deciphering the immunological relevance
of LC over dermal DC in chimeric mice. This feature has allowed
the generation of elegant chimeric mice in which LCs could be
of host origin while dermal and other DCs were of donor origin.
Thus the individual function of LCs could be addressed. LCs were
found to be unable to initiate T cell dependent immunity when
challenged with a herpes simplex virus (HSV) type 1 skin infec-
tion (Allan et al., 2003). Similarly, LCs from the vaginal mucosa
are not able to present HSV type 2-derived antigens to CD4+ T
cells (Zhao et al., 2003). Although the biological function of LCs
in vivo still raises much debate, it is now clearer that a major role
of LCs is in maintaining immune tolerance (Shklovskaya et al.,
2011).
MONOCYTE-DERIVED DCs
Under non-inﬂammatory conditions, monocytes can give rise to
CD11b+ MoDCs in non-lymphoid organ, and their development
is in part dependent onMCSF-R signaling (Bogunovic et al., 2009;
Ginhoux et al., 2009). However the contribution of monocytes to
the DC pool is by far more important under inﬂammatory condi-
tion. Pathogen recognition by CD11c−MHCII− bloodmonocytes
leads to their differentiation into CD11c+MHCII+ MoDCs that
express GR1/LY6C pointing to their monocytic origin (Leon et al.,
2004; Hohl et al., 2009; Nakano et al., 2009), becoming thereafter
the dominant DC population. Until recently, the contributions of
MoDCs to pathogen infections have been largely ignored. Recent
detailed analyses of their antigen-capturing, processing, and pre-
sentation capacity revealed that they are strikingly efﬁcient at both
direct and cross-presentation of antigens and at least under cer-
tain conditions as good as CD8α and CD103+ DCs (Cheong et al.,
2010). Under inﬂammatory conditions, MoDCs have been found
to be the main population presenting antigens in the T cell area
(Ingersoll et al., 2011). Hence, blood monocytes serve as an emer-
gency reservoir of antigen presenting cells that efﬁciently recognize
pathogens and their associated danger signals and rapidly induce
specialized antigen presentation machinery. Based on the short
kinetic of differentiation observed in vivo, it is likely that so called
“DC genes” are poised to enable rapid differentiation into MoDCs
to efﬁciently counter pathogen attack. The characterization of
new markers that clearly identify MoDCs from cDCs in inﬂamed
tissues will open the door for a better understanding of the molec-
ular mechanisms that drive monocyte differentiation intoMoDCs
(Cheong et al., 2010; Siddiqui et al., 2010).
DC DEVELOPMENT
Ontogeny
The hematopoietic system is hierarchically organized (Figure 2).
Long-term repopulating hematopoietic stem cells (HSC) con-
stantly self renew but can also give rise to short-term repopulating
cells that have lost much of their self-renewal capacity. These
precursors differentiate further into the multi-lineage progenitor
(MPP). MPP can give rise to both the common-lymphoid prog-
enitor (CLP) and the common myeloid progenitor (CMP). Both
CLP and CMP can differentiate into several DC subsets (Manz
FIGURE 2 | Ontogeny of DC precursors. Short-term HSCs commit into
multipotent progenitors that give rise to either a common-lymphoid
progenitor (CLP) or a common myeloid progenitor (CMP). A population that
lies downstream of CMP has been found to differentiate either into DC or
macrophages, and was therefore named the macrophage-dendritic cell
progenitor (MDP). Full commitment to the DC lineage is acquired at the CDP
stage (common DC progenitor) where a CDP can either differentiate into
plasmacytoid DCs (pDCs) or into a pre-DC. The latter will further differentiate
into mature conventional DCs (cDCs) in the peripheral tissues, or secondary
lymphoid organs.
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et al., 2001). This dual origin of DCs has provoked controversy
in the ﬁeld. However, recent studies have clariﬁed the origin of
DCs. Under steady-state conditions, the two main populations of
DCs, the cDCs and pDCs, have both been shown to arise from
a common dendritic cell precursor (also called the CDP) found
in the bone marrow. CDPs are devoid of macrophage potential
and exclusively give rise to DCs in vitro and in vivo (Naik et al.,
2007; Onai et al., 2007). Once generated CDPs develop either into
pDCs in the bone marrow, or give rise to pre-cDCs that are able
to migrate from bone marrow to lymphoid and non-lymphoid
organs to further mature into cDCs (Naik et al., 2006). The CDP
is thought to originate from a bipotential macrophage/DC prog-
enitor (MDP) that can generate either DCs or macrophages (Fogg
et al., 2006).
EXTRACELLULAR CUES DRIVING DC DEVELOPMENT
Development of early DC precursors is directed by the inter-
play between extrinsic cytokine signals such as Flt3, macrophage
colony-stimulating factor (M-CSF), granulocyte-macrophage
colony-stimulating factor (GM-CSF), and transcription factors
PU.1, Ikaros, and Gﬁ-1. A key determinant of the development
of DC precursors at steady-state is the Flt3:Flt3L pathway. Mice
that lack Flt3L, or its receptor Flt3, have a severe reduction in
conventional and pDC subsets (McKenna, 2001; Waskow et al.,
2008). Conditional expression, or exogenous administration of
Flt3L, results in a dramatic expansion of DCs in secondary lym-
phoid tissues (Maraskovsky et al., 1996;Manfra et al., 2003). Thus,
Flt3 and Flt3L are pivotal in driving DC ontogeny. Coordinate
regulation of Flt3 signaling is mediated through Stat3 but is dis-
pensable for differentiation of DCs via GM-CSF signaling which
is important for driving the differentiation of monocyte-derived
DC development in an inﬂammatory setting (Laouar et al., 2003;
Onai et al., 2006).
The growth factor M-CSF is well known to promote the devel-
opment of macrophages and monocytes. The ﬁrst example for
a function of M-CSF in DC development was uncovered by Gin-
houx et al. (2006),who found thatmice lacking theM-CSFR failed
to generate LCs, highlighting the critical role of M-CSFR/M-CSF
axis in the generation of this unique DC subset. Although this
pathway is thought to be dispensable for the generation of cDC
and pDC, recently, a novel role for M-CSF in DC development has
been uncovered. pDCs and cDCs can be generated from Flt3L−/−
bone marrow cells when cultured in presence of M-CSF (Fancke
et al., 2008). In addition the injection of M-CSF into mice leads
to increased pDCs and cDCs numbers. Nevertheless, the effect of
M-CSF on steady-state DCs (except from the LC) is modest when
compared with the inﬂuence of Flt3 in steady-state DC develop-
ment. The M-CSFR/M-CSF axis would be predicted to be more
critical in the generation of MoDCs during a pathogen attack, but
this pathway remains to be fully elucidated.
TRANSCRIPTION FACTORS DRIVING DC DEVELOPMENT
TRANSCRIPTION FACTORS REGULATING EARLY DC DEVELOPMENT
The differentiation of hematopoietic precursor cells into differ-
ent DC lineages is a well orchestrated process controlled in large
part by transcription factors that are modulated by extracellular
cues such as cytokines. The transcriptional networks that guide the
development of B and T cells, particularly in early hematopoiesis,
are relativelywell deﬁned. In contrast, the transcription factors that
speciﬁcally regulate DC differentiation have only now begun to be
elucidated. This has been facilitated by the use of lineage-speciﬁc
knockout mice and elegant lineage tracing approaches.
These transcription factors can be broadly divided into those
that are required or act early in DC development in DC progeni-
tors (Gﬁ-1, Pu.1), and those whose major actions affect DC subset
speciﬁcation late inDCdevelopment (E2.2, Spi-B, IRF8, Id2,Nﬁl3,
Batf3).
Gﬁ-1
Gﬁ-1 is a zinc-ﬁnger critical for DC ontogeny. Mice lacking Gﬁ-1
show a global reduction in DC numbers but increased frequency
of LCs (Rathinam et al., 2005). Interestingly, Gﬁ-1−/− bone mar-
row progenitors cultured in vitro in presence of Flt3L or GM-CSF
fail to produce DC and instead develop into macrophages. Gﬁ-1
antagonizes PU.1 activity through direct protein interaction and it
seems plausible that the aberrant macrophage potential observed
in Gﬁ-1−/− bone marrow progenitors reﬂects failed repression of
PU.1 binding to its positive regulatory elements, resulting in a
macrophage rather than a DC fate (Spooner et al., 2009).
PU.1
PU.1 (encoded by the gene Sfpi1) belongs to the Ets family of tran-
scription factors. Until recently, its role in DCs has been unclear
due to disparate studies – the ﬁrst reporting a deﬁcit in DC dif-
ferentiation (Anderson et al., 2000) and the second reporting
apparently normal DC development in the absence of PU.1 (Guer-
riero et al., 2000). These studies could not distinguish whether
PU.1 played a role at the stage of DC commitment or whether
its main action was in multipotent progenitors. Conditional dele-
tion of PU.1 at different stages of DC development highlighted the
requirement of PU.1 for DC commitment as differentiation was
abrogated in absence of PU.1 (Carotta et al., 2010). Furthermore,
PU.1 lies upstream of FLT3 and GM-CSFR and is required for the
development of DCs via both pathways. Thus, PU.1 is a central
player in the generation of both steady-state DCs and presumably
inﬂammatory DCs although the complex interactions of PU.1 in
coordinating DC differentiation remain to be fully explored.
TRANSCRIPTION FACTORS REGULATING LATE DC DIFFERENTIATION
While a number of transcription factors delineate the development
of precursor cells that ultimately give rise to DCs, speciﬁcation
of individual DC subset identity appears to be a late event that
is guided a handful of transcription factors (see Table 2). These
can be broadly divided into three pathways of regulation – those
transcription factors that predominantly inﬂuence (i) the pDCs
(namely E2-2 and Spi-B), (ii) the CD8α+ and CD103+ lineages
(IRF8, Id2, EB4BP, and Batf3), and (iii) the non-CD8α+ DC
lineages (IRF2, IRF4).
Regulation of pDCs by E2-2
E proteins constitute a family of basic helix-loop-helix (bHLH)
transcription factorwhose functionhave beenmost clearly deﬁned
in B lymphocytes (de Pooter and Kee, 2010). The expression of E
proteins is modulated by inhibitor of DNA-binding (ID) proteins
which can bind E proteins to prevent their binding to DNA tar-
gets. To date three mammalian E proteins have been described
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Table 2 |Transcription factors guiding steady-state DC subset development.
Transcription factor Transcription factor family Phenotype Reference
PU.1 (SPI1, Sfpi1) Ets-domain transcription factor binds to
PU box sequences
Required for development of all DC
subsets
Anderson et al. (2000), Guerriero et al. (2000),
Carotta et al. (2010)
Irf2 Interferon regulatory factor, inhibits the
IRF1-mediated activation of IFNα/β
Alters pDC ratios; reduction in
CD8− DCs and LCs
Ichikawa et al. (2004)
Irf4 Interferon regulatory factor Required for non-CD8α+ DC lineage
development
Suzuki et al. (2004), Tamura et al. (2005)
Irf8 (ICSBP) Interferon regulatory factor Required for pDC and most cDC
development
Schiavoni et al. (2002), Aliberti et al. (2003),
Tsujimura et al. (2003), Schiavoni et al. (2004),
Tailor et al. (2008)
Gﬁ-1 Zinc-ﬁnger protein, repressor 50% reduction in cDC and pDC
subsets and increased LCs
Rathinam et al. (2005)
Id2 Inhibitor of DNA-binding family containing
helix-loop-helix domains (HLH)
Required for development of
CD103+ DCs and CD8α+ DCs in
PLN and spleen; not required for
DCs in MLNs.
Hacker et al. (2003), Ginhoux et al. (2009),
Jackson et al. (2011)
E4BP4 (NFIL3) PAR-related basic leucine zipper (bZIP)
transcription factor
Required for development of
CD8α+ DCs
Kashiwada et al. (2011)
E2-2 (Tcf4) E protein containing basic helix-loop-helix
domains (bHLH)
Required for development of pDCs
and their maintenance
Cisse et al. (2008), Ghosh et al. (2010)
Stat3 Signal transducer and activator of
transcription
Signiﬁcant reduction in cDCs Laouar et al. (2003)
Stat5a/b Signal transducer and activator of
transcription
Inhibits pDC development by
interacting with Irf8, reduced cDC
and pDC subsets
Esashi et al. (2008)
Ikaros (Ikzf1) Zinc-ﬁnger DNA-binding protein Absence of most DCs. pDCs
speciﬁcally lost in hypomorphic
mutant
Wu et al. (1997), Allman et al. (2006)
Batf3 bZIP, heterodimerizes with Jun Failure to develop CD103+ DCs;
impaired survival of precursor
CD8α+ DCs
Hildner et al. (2008), Edelson et al. (2010),
Jackson et al. (2011)
RelB Rel homology domain family, interacts
with NFκB family
Loss of CD8− DCs Burkly et al. (1995), Wu et al. (1998)
SpiB Ets-domain transcription factor Required for human pDC
differentiation
Schotte et al. (2004)
(E2a, HEB, E2-2) that act on their targeted sequence (CACCTG
E-box) either as homodimers or heterodimers. The ﬁrst indication
that E proteins played important roles in pDCdifferentiation came
from the study by Spits et al. (2000),where the overexpression of Id
proteins, which sequester E proteins, impaired in vitro pDC devel-
opment but left cDC differentiation intact. Subsequent analysis
uncovered that E2-2, encoded by the gene Tcf4, was a key deter-
minant of pDC differentiation. Germline or conditional deletion
of E2-2 led to a complete loss of the pDC and abolished the abil-
ity of mice to respond to unmethylated DNA (Cisse et al., 2008).
Through the binding of E2-2 to many pDC signature genes (Irf8,
Irf7, SpiB, BDCA-2) it has been proposed as a master regulator of
the pDC compartment. In line with this hypothesis, the depletion
of E2-2 in mature pDC led to a predominance of cDC-like cells
implying that E2-2 plays a pivotal role inmaintaining pDC cell fate
(Ghosh et al., 2010). However, in this setting it is difﬁcult to sepa-
rate the contributionof expansionof the pre-existing cDCs asmol-
ecular analyses showed enrichment of the conventional DC genes
rather than a pure signature. Nevertheless, pDCs are particularly
sensitive to E2-2 concentration as both E2-2-deﬁcient mice and
rare patients with haploinsufﬁciency (Pitt–Hopkins syndrome)
show impaired pDC formation and function (Cisse et al., 2008).
Spi-B
A second transcription factor that inﬂuences the development
of pDCs is Spi-B, a member of Ets family transcription factor
(Schotte et al., 2004). In contrast to the loss of PU.1, deﬁciency
of Spi-B affects only the pDC compartment. Interestingly, over
expression of Spi-B in human pDCs impairs Id2 expression and
consequently E2-2 activity is enhanced suggesting that Id2 is a key
regulator of the cDC/pDC balance (Nagasawa et al., 2008). How-
ever, the capacity for E2-2 to promote pDC differentiation was
abolished in these DCwhen Spi-B expression was ablated showing
that Spi-B and E2-2 are jointly necessary to efﬁciently drive devel-
opment of human precursors into the pDC lineage (Nagasawa
et al., 2008).
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THE IRF8–ID2–BATF3 AXIS REGULATES CLASSICAL
CROSS-PRESENTING DCs
IRF8
Interferon regulatory factor 8 (also called the interferon consensus
sequence-binding protein, or ICSBP) regulates the development
of both cDCs and pDCs and is highly expressed on the CDP.
Mice deﬁcient in IRF8 lack many mature DC subsets including
CD8α+ DCs and LCs (Schiavoni et al., 2002, 2004). In addition,
IRF8 controls functional features such as TLR9 and IFN-α produc-
tion in pDCs and IL-12 production in CD8α+ DCs (Tailor et al.,
2008). Irf8−/− mice are more susceptible to viral infection but
also develop amyeloproliferative syndrome characterized by over-
production of granulocytes (Holtschke et al., 1996). This suggests
that while IRF8 is important for conventional DC development,
it may also be required for the generation or maintenance of the
upstream MDP progenitor that can give rise to monocytes, cDCs,
and pDCs.
Id2
The expression of Id2 is highest in CD8α+ and CD103+CD11b−
DCs but it is nevertheless broadly expressed by all conventional
DC subsets (Ginhoux et al., 2009; Jackson et al., 2011). Loss
of Id2 results in the failure of these two subsets, CD8α+ and
CD103+ DCs, to develop in skin-draining lymph nodes and
spleen. CD103+CD11b+ DCs found in the lymph nodes draining
the gut together with CD4+ and CD4−CD8α− DCs in lymphoid
tissues, appear to develop normally (Hacker et al., 2003; Ginhoux
et al., 2009; Edelson et al., 2010). Through its action in regulat-
ing E protein binding, Id2 appears to plays a pivotal role in the
maintenance of conventional DC identity. Multiple E proteins are
expressed by DCs so precisely how these are regulated, and which
E proteins (E2A, E2-2, or HEB) are the critical targets of Id2 is
unclear. Understanding the balance between E proteins and Id
proteins in cDCs will be required to understand why Id2 plays
such an key role in CD8α+ and CD103+CD11b− DCs and how
differentiation of such subsets might be enhanced.
Nﬁl3 (also known as E4BP4)
E4BP4 is a mammalian basic leucine zipper (bZIP) transcription
factor that is required for the development of NK cells, and is a
key regulator of cytokine production in other hematopoietic lin-
eages (Gascoyne et al., 2009; Kamizono et al., 2009; Kashiwada
et al., 2011; Kobayashi et al., 2011). In NK cells E4BP4 acts in a
dose dependent manner downstream of the IL-15 receptor and
regulates Id2 expression (Gascoyne et al., 2009; Kamizono et al.,
2009). Thus, it has been found that induction of E4BP4 is impor-
tant for the development of CD8α+ DCs (Kashiwada et al., 2011).
E4BP4−/− mice exhibit impaired IL-12 production upon TLR3
activation, and failed to cross-prime CD8+ T cells against cell-
associated antigens. CDPs deﬁcient in E4BP4 displayed reduced
BATF3 expression and enforced expression in these cells rescued
CD8α+ DCs development in vitro (Kashiwada et al., 2011). Thus,
E4BP4 is emerging as an important regulator of conventional DC
development.
Batf3
Batf3 is a bZIP transcription factor (also known as Jun dimer-
ization protein p21SNFT) that represses NFAT–AP1 activity by
competing with FOS for JUN dimerization (Dorsey et al., 1995;
Echlin et al., 2000). It provoked enormous interest in the DC
ﬁeld when it was shown to play a critical role in DC differenti-
ation. Indeed, it was the ﬁrst description of a transcription factor
that appeared to have an exclusive role in the development of
the CD8α+ DC subset. The fact that deletion of Batf3 resulted
in increased susceptibility to various pathogen infections such as
West Nile virus, inﬂuenza virus, Listeria monocytogenes, and Tox-
oplasma gondii (Hildner et al., 2008; Desch et al., 2011; Edelson
et al., 2011; Mashayekhi et al., 2011) and critically impaired cross-
priming was striking (Hildner et al., 2008). More recently it has
been described to be involved in the development of migratory
cross-presenting CD103+CD11b− DCs in peripheral lymphoid
tissues (Edelson et al., 2010), but not in gut lymphoid tissue
CD103+CD11b+ DCs (Bar-On et al., 2010). However, although
Batf3−/− mice show a reduction in the frequency of CD8α+ DCs,
particularly in the spleen, it is now clear that CD8α+ DCs are
indeed present in the absence of Batf3 (Edelson et al., 2011; Jack-
son et al., 2011). Thus in contrast to the early suggestions, Batf3
appears to exclusively regulate the development of CD103+ DC
while CD8α+ DC precursors develop although they seem unable
to cross-present exogenous antigens to CD8+ T cells. This sug-
gests that some stages in DC maturation may be perturbed in the
absence of Batf3.
CD8α− DC, MONOCYTE-DERIVED DC LINEAGES, AND
TRANSCRIPTIONAL REGULATION
Until recently, the capacity to cross-present antigens was a feature
attributed almost exclusively to CD8α+ and CD103+ DCs. This
distinction gained some foothold with the notion that particu-
lar DC subsets possess unique molecular machinery intrinsic to
these subsets exclusively enabling them to cross-present (Schnor-
rer et al., 2006). However, in other settings, it was clear that
non-CD8α+ lineage cells could also perform such functions. This
was poignantly highlighted by the systematic characterization of
the capacity for MoDCs to efﬁciently cross-present antigens, par-
ticularly in the inﬂammatory setting, demonstrated that induction
of cross-presentingmachinery could occur in different DC subsets
when subjected to speciﬁc stimuli (Cheong et al., 2010).
Non-CD8α+ DC lineages are composed of DN and CD4+ DCs
together withMoDCs.Much less is known about the transcription
factors that regulate the fate decisions of these subsets although it is
clear that at least the conventional subsets in this group are signif-
icantly inﬂuenced by IRF2 (Hida et al., 2000; Honda et al., 2004;
Ichikawa et al., 2004; Arakura et al., 2007), IRF4 (Suzuki et al.,
2004; Tamura et al., 2005), and RelB (Burkly et al., 1995;Wu et al.,
1998). At least some of these pathways are also likely to regulate
MoDCs. This could potentially happen through the role of IRF4 in
coordinating signals from GM-CSF stimulation through the NF-
κB pathway (Gilliet et al., 2002). It will be important to dissect
the network of transcription factors that drive not only CD8α−
DC development but also function. This latter feature seems par-
ticularly important where a property such as cross-presentation
is inducible and transcription factors such as Id2 and Batf3 are
broadly expressed in the non-CD8α− DC lineages but not obvi-
ously required for the development of these subsets. They may
indeed be important for maturation or localization of DCs.
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NOMENCLATURE, DC SUBSETS, AND THE TOOLS
NECESSARY FOR PRECISE DEFINITIONS
Key steps in understanding DC subsets has come from detailed
phenotypic characterization made possible through the devel-
opment of novel antibodies combined with the power of ﬂow
cytometry. These descriptions have been signiﬁcantly extended by
elucidation of the anatomical localization of particular DC sub-
set, the precursors from which they arise and the identiﬁcation
of unique or restricted functions that can now be attributed to
particular DC subsets. For example, CD8α+ and CD103+ DCs
are the dominant DC subsets that cross-present soluble and cell-
associated antigens and present viral antigens toCD8+ T cells (den
Haan and Bevan, 2002; Allan et al., 2003; Belz et al., 2004a,b, 2005;
Bedoui et al., 2009). While a number of seminal studies that have
identiﬁed a new DC subset or function are critical to the devel-
opment of the ﬁeld, they have not always led to clariﬁcation of
the contributions of DCs, or DC subsets, to immunoregulation of
responses. This arises largely because surface markers or receptors
are expressed by multiple DC subsets and in many instances, a
broader range of immune cells. Thus, with regard to the capacity
to cross-present antigens, MoDCs have recently also been discov-
ered to be very efﬁcient in shuttling antigen into this pathway,
particularly in an inﬂammatory setting (Cheong et al., 2010).
One approach to this problem is to focus on the molecular
wiring of cells – that is, the transcription factors – to develop a
deﬁnitivemapof DC identity (Satpathy et al., 2011). This approach
indeed offers a way forward. However, deletion of speciﬁc DC
populations is premised on the notion that presence or absence
of a transcription factor results in a complete loss or alternately,
exaggeration of DC subsets or their functions. Loss of some tran-
scription factors such as Irf4, Irf8, and Id2 seem to demonstrate
relatively deﬁnitive outcomes with complete loss of some DC sub-
sets. Certainly, mice engineered to allow conditional deletion of
a gene in a cell-speciﬁc manner (e.g., driven by CD11c) allows
analysis of the intrinsic requirement for factors allows delineation
of phenotypes that may arise due to extrinsic signals. Similar
approaches have also been used where a cell-speciﬁc promoter
drives conditional deletion of a cell type. A key example of this is
the development of mice in which CD11c+ cells can be deleted by
treating them with diptheria toxin (CD11c–DTRmice; Jung et al.,
2002). This provides an elegant model for examination of cDCs
but it was quickly realized that other cell types (such as inﬂamed
lung epithelial cells) expressed CD11c and therefore generation
of bone marrow chimeric mice was necessary to fully utilize this
model without confounding effects (Sapoznikov and Jung, 2008).
In biology, this “black and white” model seldom reﬂects real-
ity and it is not clear that DC differentiation into subsets is a
purely linear process. Loss of the ability to detect a DC subset
depends mainly on the same tools we have used to identify them
in the ﬁrst instance. These approaches do not generally distinguish
between two important stages of developmental arrest – ﬁrstly,
complete ablation of a lineage, and secondly, the formation of
the immediate precursors of that lineage that then fail to receive
the necessary signals for DC progenitors to develop into fully
matured cells in the peripheral tissues. The former situation iden-
tiﬁes factors that are deﬁnitively required for the formation of a
DC subset; the latter allows detailed dissection of the factors that
inﬂuence thematuration and survival of DC subsets in the periph-
ery. Distinguishing between these two cases is facilitated by the
use of genetically modiﬁed mice in which a transcription factor is
linked to a ﬂuorescent reporter allowing rare precursor cells to be
identiﬁed when most of the population does not survive to matu-
rity. This was ﬁrst identiﬁed in mice expressing green ﬂuorescent
protein linked to Ror(c)t, an important transcription factor for
the development of lymphoid-tissue inducer (LTi) cells (Schmutz
et al., 2009; Chappaz and Finke, 2010). Treatment of these reporter
mice with IL-7/IL-7R mAb complexes revealed that progenitor
cells were in fact formed in the absence of Ror(c)t but they did not
develop into cells that could colonize and form secondary lym-
phoid tissues due to impaired IL-7 signaling. Similarly, Batf3 was
initially described (Hildner et al., 2008) to unequivocally regu-
late the development of CD8α+ DCs and was later discovered to
also regulate CD103+ DCs (Edelson et al., 2010). By analyzing the
expression patterns of ID2 in Batf3−/− mice using the Id2GFP/GFP
strain (Jackson et al., 2011), it was discovered that both in vitro and
in vivo CD8α+ DC precursors do develop in the absence of Batf3
although their persistence, particularly in spleen, was diminished
(Edelson et al., 2011; Jackson et al., 2011). These two examples
highlight that careful dissection of phenotypes is critical and that
complementary methods to analyze the expression of transcrip-
tion factors and consequences of their loss provides a real strength
in tackling the difﬁcult questions of the future.
Overall, the factors that determine differentiation patterns of
individual DC subsets with unique functions are complex. Estab-
lishment of the features that deﬁne an individual DC subset’s
identity, their maintenance and differentiation is unlikely to be
simplistic and rely on a single phenotypic marker or transcription
factor. A more likely scenario is that DC subset development is
determined by combinatorial interactions between transcription
factors to guide fate decisions (Lin et al., 2010;Wilson et al., 2010).
Analyses of genome wide DNA-binding data will be critical for
understanding precisely how these different transcription factors
work together to deﬁne the different populations of DCs that are
necessary to provide protective immunity.
KEY QUESTIONS AND FUTURE DIRECTIONS
Our current understanding of DC commitment and differen-
tiation at a steady-state and during pathogen infection is lim-
ited, especially when compared to the extensive understanding
of regulatory networks that guide fate decisions in B cells and
CD4+ T cells. In addition, the mechanisms that guide the emer-
gence inﬂammatory DCs and the induction of protective cross-
presentingmachinery offer a fertile ﬁeld for discovery in the future.
Collectively, understanding the complex and multilayered cir-
cuitry that integratesDC location, expression of surfacemolecules,
components of the antigen processing and presentation machin-
ery together with and understanding of the molecular wiring, and
potential rewiring of DC subsets will be essential. This informa-
tion will lead to a more complete picture of the roles of DCs and
the DC network in maintaining immune tolerance and immunity
and may prove pivotal to improvements in the clinical efﬁcacy
of therapeutic approaches. Solving the following, and other, crit-
ical questions in the ﬁeld of DC biology will be instrumental in
progressing discoveries in the ﬁeld.
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1. Do individual transcription factors, or alternately, combinato-
rial transcriptional programs involving networks of transcrip-
tion factors determine DC subset speciﬁcation?
2. How do DC subsets that emerge during inﬂammatory setting
reﬂect those identiﬁed at steady-state?
3. How is the constitutive cross-presenting machinery that main-
tains tolerance through presentation of self-antigens at steady-
state, and is dominant inCD8α+ andCD103+ DCs during viral
infection, induced inmultipleDC subsets during inﬂammation
or pathogen challenge?
4. Can this inductive process be harnessed and how?
5. How does the MDP engage the “DC program”?
6. How does DC lifespan affect immunity?
7. How is developmental plasticity is maintained to ensure
immunity?
The challenge now is to develop the skill sets, tools, and tech-
nologies that will enable us to embark on dissection of these core
features of DCs to open the pathway for targeted use of this cell
type.
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